EAU 2017 | What does the earlier application of immune-oncology agents mean for urological cancer teams?

Joaquim Bellmunt

Joaquim Bellmunt, MD, PhD, from the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter